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Conjugated linoleic acid versus high-oleic acid sunflower oil: effects on
energy metabolism, glucose tolerance, blood lipids, appetite and body
composition in regularly exercising individuals
Abstract
The aim of this study was to measure the effects of 12 weeks of conjugated linoleic acid (CLA)
supplementation on body composition, RER, RMR, blood lipid profiles, insulin sensitivity and appetite in
exercising, normal-weight persons. In this double-blind, randomised, controlled trial, sixty-two non-obese
subjects (twenty-five men, thirty-seven women) received either 3.9 g/d CLA or 3.9 g high-oleic acid
sunflower oil for 12 weeks. Prior to and after 12 weeks of supplementation, oral glucose tolerance, blood lipid
concentrations, body composition (dual-energy X-ray absorptiometry and computerised tomography scans),
RMR, resting and exercising RER and appetite were measured. There were no significant effects of CLA on
body composition or distribution, RMR, RER or appetite. During the oral glucose tolerance tests, mean
plasma insulin concentrations (0, 30, 120 min) were significantly lower (P equals 0.04) in women who
supplemented with CLA (24.3 (SD 9.7) to 20.4 (SD 8.5) mU/ml) compared to high-oleic acid sunflower oil
control (23.7 (SD 9.8) to 26.0 (SD 8.8) mU/ml). Serum NEFA levels in response to oral glucose were
attenuated in both men and women in the CLA (P equals 0.001) compared to control group. However, serum
total cholesterol and LDL-cholesterol concentrations decreased in both groups and HDL-cholesterol
concentrations decreased in women over 12 weeks (P equals 0.001, P equals 0.02, P equals 0.02, respectively).
In conclusion, mixed-isomer CLA supplementation had a favourable effect on serum insulin and NEFA
response to oral glucose in non-obese, regularly exercising women, but there were no CLA-specific effects on
body composition, energy expenditure or appetite.
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The aim of this study was to measure the effects of 12 weeks of conjugated linoleic acid (CLA) supplementation on body composition, RER,
RMR, blood lipid profiles, insulin sensitivity and appetite in exercising, normal-weight persons. In this double-blind, randomised, controlled
trial, sixty-two non-obese subjects (twenty-five men, thirty-seven women) received either 3·9 g/d CLA or 3·9 g high-oleic acid sunflower oil for
12 weeks. Prior to and after 12 weeks of supplementation, oral glucose tolerance, blood lipid concentrations, body composition (dual-energy
X-ray absorptiometry and computerised tomography scans), RMR, resting and exercising RER and appetite were measured. There were no sig-
nificant effects of CLA on body composition or distribution, RMR, RER or appetite. During the oral glucose tolerance tests, mean plasma insulin
concentrations (0, 30, 120min) were significantly lower (P¼0·04) in women who supplemented with CLA (24·3 (SD 9·7) to 20·4 (SD 8·5) mU/ml)
compared to high-oleic acid sunflower oil control (23·7 (SD 9·8) to 26·0 (SD 8·8) mU/ml). Serum NEFA levels in response to oral glucose were
attenuated in both men and women in the CLA (P¼0·001) compared to control group. However, serum total cholesterol and LDL-cholesterol
concentrations decreased in both groups and HDL-cholesterol concentrations decreased in women over 12 weeks (P¼0·001, P¼0·02, P¼0·02,
respectively). In conclusion, mixed-isomer CLA supplementation had a favourable effect on serum insulin and NEFA response to oral glucose
in non-obese, regularly exercising women, but there were no CLA-specific effects on body composition, energy expenditure or appetite.
Exercise metabolism: Insulin sensitivity: Body fat distribution: CLA isomers
There is recent scientific and clinical interest in conjugated
linoleic acid (CLA), for its putative role in enhanced
immune function, altered substrate metabolism and body com-
position changes. Linoleic acid is an 18-carbon PUFA with
two double-bonds in the 9 and 12 positions (cis configuration).
In CLA, the double bonds reside in either the 9 and 11
positions (predominant form in food), the 10 and 12 positions
or the 11 and 13 positions. The primary dietary source of CLA
is found in food products from ruminant animals, such as
cheese, milk and meat.
In animal and tissue studies, CLA has been associated with
lower blood lipid levels, reduced body fat accumulation and
increased fat oxidation, increased lean mass accretion,
improved skeletal muscle insulin sensitivity and reduced
food intake (Houseknecht et al. 1998; Rahman et al. 2001).
However, there appear to be large inter-species differences
in response to CLA that may limit the interpretation or extra-
polation to human studies. For example, Terpstra (2001) has
estimated that the normalised, body fat-lowering effects of
CLA are 7-fold higher in mice than in man. Therefore, for
the purposes of this paper, only the results of human studies
will be discussed. However, human studies examining the
metabolic effects of CLA supplementation show equivocal
results.
A series of well-controlled studies undertaken at the Uni-
versity of California found that 64 d of CLA administration
(3·9 g/d) in seventeen healthy female volunteers did not
result in changes in body composition, energy expenditure,
substrate utilisation, appetite or plasma lipid profile (Medina
et al. 2000; Zambell et al. 2000; Benito et al. 2001). Failure
to show an effect in these studies may be due, in part, to
low statistical power, or differences in isomer-specific effi-
cacy. The CLA used in these studies contained less than
25% t10c12 and less than 18% c9t11 isomers. In contrast,
studies including more than fifty free-living overweight volun-
teers found that CLA administration of $3·4 g/d for 12 weeks
was associated with significant reductions in body fat mass
compared to placebo administration (Blankson et al. 2000).
*Corresponding author: Professor Estelle V. Lambert, fax þ27 21 6867530, email vlambert@sports.uct.ac.za
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In a recent study, Kamphuis et al. (2003a), also found that
CLA administration resulted in a significant increase in lean
body mass and associated changes in resting metabolic rate,
as well as reductions in appetite sensations.
Changes in body fat distribution have also been demon-
strated with CLA supplementation. Risérus et al. (2001)
demonstrated a significant decrease in sagittal abdominal
area in a small sample of obese, middle-aged men with
signs of the metabolic syndrome when supplemented with
4·2 g/d of CLA for 4 weeks. However, they were unable to
demonstrate any associated changes in blood lipids or glucose
and insulin concentrations with CLA supplementation. In a
follow-up study, the same group demonstrated that adminis-
tration of 3·4 g/d of an enriched t10c12 CLA isomer for 12
weeks increased insulin resistance, fasting glucose and dys-
lipidaemia in abdominally obese men (n 19) (Risérus et al.
2002). However, these adverse metabolic effects were not
found when a commercial CLA mixture (35·9% t10c12 and
35·4% c9t11) was administered. Further to this study, 12
weeks of supplementation with a similar dose of predomi-
nantly c9t11 isomer-enriched CLA resulted in a significant
reduction in insulin sensitivity in abdominally obese men
(Risérus et al. 2004a). Therefore, these studies highlight the
complex relationships between CLA isomers and dose, meta-
bolic phenotype, and the potential underlying mechanisms of
effect of CLA in influencing glucose and lipid metabolism
in vivo (Risérus et al. 2004a).
Furthermore, there are few studies in which these relation-
ships have been interrogated in persons who are regularly
exercising (Thom et al. 2001). This has important impli-
cations, as changes in substrate oxidation and tissue sensitivity
to insulin associated with training may interact with the effects
of CLA administration on body composition, glucose and lipid
metabolism. Moreover, these individuals constitute a popu-
lation who may be likely to use dietary supplements for
health and weight control. By relating changes in adipose
tissue mass to changes in whole body substrate oxidation
and metabolism, satiety and energy intake, we may begin to
understand the potential mechanisms underlying these effects.
The primary aim of the present study was, therefore, to
measure the effects of CLA administration versus a high-
oleic acid sunflower oil control, on whole body substrate oxi-
dation at rest and during exercise, resting energy expenditure,
body composition and regional adipose tissue distribution in
regularly exercising individuals. A secondary aim was to
examine the effects of CLA on blood lipid profiles, glucose
homeostasis and insulin sensitivity in already exercising,
normal-weight persons.
Methods
Subjects
Sixty-four regularly exercising subjects (twenty-six men,
thirty-eight women), between the ages of 21 and 45 were
recruited from the fitness centre of the Sports Science Institute
of South Africa or a similar facility. Persons were excluded on
the basis of chronic illness or medication, existing lipid dis-
orders, obesity (BMI . 30 kg/m2), diabetes or hypertension.
Women who were lactating or who were planning on becom-
ing pregnant were also excluded. Individuals were also
excluded if they were currently taking nutritional supplements,
other than a general multi-vitamin supplement. Only subjects
who were exercising three or more times per week, and who
had been exercising at this level for more than 6 months,
were included. Furthermore, subjects must have been weight
stable (^2–3 kg) for 3 months preceding the trial.
The subjects were informed of the nature of the trial, and all
potential risks and benefits were explained to them. Informed
written consent was obtained from all subjects before the start
of the trial. The Research and Ethics Committees of the
Faculty of Health Sciences, University of Cape Town, South
Africa, approved the study.
Protocol
The study was a double-blind, controlled trial and the subjects
were randomly assigned to one of two groups, receiving either
3·9 g CLA supplement (Formule Naturelle Ltd, Johannesburg,
South Africa, containing Clarinole from Loders Croklaan,
Lipid Nutrition, Wormerveer, The Netherlands) or control
supplement (3·9 g high-oleic acid sunflower oil, HOSF), per
day. The CLA capsule contained 65·9% CLA, of which the
main constituents were c9t11 isomer (29·7%) and c10t12
isomer (30·9%), and also contained minimal amounts of
other CLA isomers (2·9%). In addition, the capsule contained
oleic acid (18: 1n-9, 24·7%), and a small amount of palmitic
acid (16: 0; 3·5%), stearic acid (18: 0; 1·3%) and linoleic acid
(18: 2n; 9; 12; 1·9%).
Experimental subjects and controls were tested prior to and
at the end of the 12-week period of intervention. Every 2
weeks the subjects met with registered dietitians to report
any adverse events (e.g. diarrhoea, bloating) or any changes
in training, lifestyle or eating patterns, and to assess pill com-
pliance. In addition, at each of these visits, subjects were
asked to complete a visual analogue scale measuring hunger,
fullness, satiety and prospective intake, prior to and for 3 h fol-
lowing the ingestion of a standardised breakfast snack.
Subjects underwent preliminary screening for cardio-respir-
atory fitness; body composition by skinfold measurements,
dual-energy X-ray absorptiometry (DEXA) and computerised
tomography (CT) scans at the level of L4/L5. Oral glucose tol-
erance tests (OGTT) were conducted and blood lipid profiles
were measured. In addition, fasting RMR and RER, as well
as RER during exercise at pre-set relative low- and high-inten-
sity workloads (25% and 65% VO2max) were measured.
Eating behaviour
Prior to the intervention, the Three-Factor Eating question-
naire was administered to screen for individuals demonstrating
restrained eating, or high levels of dietary disinhibition
(Stunkard & Messick, 1985).
Dietary assessment
Subjects completed three 4 d dietary records (three weekdays
and one weekend day) during the trial, in weeks 1 (baseline),
6 and 12. These dietary records were coded by the same die-
titian, and analysed with the Food Finder Program (Medtech,
Tygerberg, South Africa).
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Training
Over the 12-week period, the subjects recorded their daily
physical training which was then quantified according to meta-
bolic equivalents (MET-h/week). In addition, physical activity
was measured using a 7 d physical activity recall questionnaire
prior to the start of the intervention, and at the end of the 12-
week period. Habitual activity was expressed as MET-h/wk
(Blair et al. 1985). The subjects were instructed to keep
their training and diet constant throughout the trial, and any
changes were recorded.
Body composition assessment
Body composition assessments were undertaken immediately
prior to and after 12 weeks of intervention. The anthropometric
measurements, including the sum of seven skinfolds (biceps, tri-
ceps, subscapular, suprailiac, abdominal, thigh and calf),
weight, height, and waist and hip circumferences were obtained.
In addition, subjects underwent precise measurement of whole
body, body composition using fan-beam DEXA.
CT was used to assess both visceral adipose tissue and sub-
cutaneous adipose tissue area (cm2); Yoshizumi et al. 1999),
using a Toshiba X-press helical scanner (Japan). Subjects
were scanned in the supine position with legs slightly flexed
and arms raised above the head. Scans were done in arrested
expiration at the L4/L5 level of the vertebra.
Visual analogue scale measures of appetite
Subjective motivation to eat (hunger, satiety, fullness and pro-
spective consumption) was assessed by repeated adminis-
tration of 100mm visual analogue scales (VAS) (Flint et al.
2000) prior to a test breakfast in the fasted state (10–12 h)
and then hourly for 3 h following the test meal. These VAS
ratings were completed in the fasted state, every 2 weeks,
through the 12-week intervention. The test breakfast com-
prised a 100 g muffin (Muffinmate CC, Cape Town, South
Africa) and 200ml pure fruit juice (Parmalat, Stellenbosch,
South Africa), which were individually packaged. The compo-
sition of the muffin per 100 g was 2749·4 kJ, 50·9 g protein,
31·6 g fat, 37·4 g carbohydrate, while the fruit juice contained
13·5 g carbohydrate/100ml.
Oral glucose tolerance test and fasting blood lipid profiles
Prior to starting the trial and after 12 weeks of supplementation
the subjects underwent a standard OGTT after a 10–12 h over-
night fast. A fasting blood sample (20ml) was drawn for the
determination of plasma glucose and insulin concentrations,
and serum triacylglycerol, total cholesterol, HDL-cholesterol,
LDL-cholesterol and NEFA concentrations. The subjects then
ingested 75 g glucose dissolved in 250ml water. Blood samples
(6ml) were drawn at 30min intervals for 2 h for the determi-
nation of plasma glucose and NEFA concentrations. Blood
was drawn at 30 and 120min post-glucose ingestion for determi-
nation of plasma insulin concentrations.
Plasma glucose concentrations were determined using
the glucose oxidase method (Glucose Analyzer 2; Beckman
Instruments, Fullerton, CA, USA) and plasma insulin con-
centrations were determined by non-specific insulin RIA
(Count-A-Coat Insulin; Diagnostic Products, Los Angeles, CA,
USA) with intra-assay and inter-assay CV of 4·5% and 6·6%,
respectively. Serum NEFA concentrations were analysed with
enzymatic spectrophotometric measurement using a commercial
kit (NEFAHalf-micro test; Roche, Mannheim, Germany). Blood
lipids were analysed using the Roche Modular Auto Analyzer.
Enzymatic colorimetric assays were used to analyse total choles-
terol, triacylglycerol and HDL-cholesterol concentrations. The
LDL-cholesterol concentrations were determined using the Frie-
dewald Formula (Friedewald et al. 1972).
Insulin sensitivity
Insulin resistance and insulin sensitivity were estimated from
fasting and glucose-stimulated blood glucose and insulin con-
centrations, based on the homeostasis (HOMA; Matthews et al.
1985) and the QUICKI (Perseghin et al. 2001) models.
The HOMA model is used as a proxy measure of insulin
resistance and correlates well to insulin resistance measured
using the euglycaemic–hyperinsulinaemic clamp (Matthews
et al. 1985; Phillips et al. 1994). It is calculated using the fol-
lowing equation:
Resistance ¼ insulin=ð22·5e2ln glucoseÞ:
The QUICKI or Quantitative Insulin Sensitivity Check model
has been shown to correlatewellwith insulin sensitivitymeasured
using the euglycemic–hyperinsulinaemic clamp, however, a
recent modification, incorporating fasting NEFA concentrations,
further improves this association (Perseghin et al. 2001). The two
equations used for this model are as follows:
QUICKI ðGb; IbÞ ¼ 1=ðlog ðGbÞ þ log ðIbÞÞ
QUICKI ðGb; Ib; NEFAbÞ ¼ 1=ðlog ðGbÞ þ log ðIbÞ
þ log ðNEFAbÞÞ
where Gb ¼ fasting glucose concentration (mg/dl); Ib ¼ fasting
insulin concentration (mU/ml); NEFAb ¼ fasting NEFA concen-
tration (mmol/l).
Insulin secretion was also assessed using the 30min insulin
increment to the30minglucose increment. In addition, the attenu-
ation of NEFA mobilisation during the OGTT was described.
Maximal oxygen uptake, energy expenditure and substrate
utilisation at rest and in response to sub-maximal exercise
All subjects were tested for VO2max and peak sustained power
output on an electronically braked cycle ergometer (Lode,
Groningen, The Netherlands) as described previously
(Hawley & Noakes, 1992). The results of the initial maximal
test were used to determine the workload that corresponded to
25% and 65% of VO2max. The CV of measurement for the
Oxycon Alpha was 1·4%.
On another day, after a 10–12 h overnight fast, subjects
arrived at the laboratory, and rested in the supine position for
30min prior to the start of each test. Energy expenditure and sub-
strate utilisation were assessed at rest, using the canopy or ven-
tilated hood technique, by measuring O2 uptake and CO2
production at 60 s intervals for 20min or until subjects reached
steady state (,5% change in RER) (VMax Metabolic Cart
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229; SensorMedics, Yorba Linda, CA, USA). From these
measurements, the resting energy expenditure and RER were
determined using the equations of Frayn (1983).
Following the resting measurements, sub-maximal exercise
was performed by the subjects at two exercise intensities
(25% and 65% of VO2max) for 15min each on a cycle erg-
ometer, with 15min seated rest separating the two bouts.
During the sub-maximal exercise session, substrate oxidation
was calculated based on the gas exchange measured using a
breath-by-breath OxyconSigma Analyser (Mijnhart, Bunnik,
The Netherlands), as described previously.
Statistical analysis
Sample size was determined using GraphPad Instate, version
2.05a (GraphPad, San Diego, CA, USA). In order to be able to
detect differences in body fat mass (kg) of 1·5 kg with a stan-
dard deviation of 1·75 (kg) and differences in body fat of
1·5% with a standard deviation of 2·0%, at an alpha level
of 0·05, and with 80% power, we required a sample size of
between fourteen and eighteen per group. This sample size
takes into consideration the Bonferroni correction for multiple
effects (gender and treatment). In addition, to detect differ-
ences in RMR of 0·6MJ/d with a standard deviation of
0·7MJ/d, we required a sample size of fourteen per group.
Two-factor, repeated measures ANOVA was used to explore
changes in body composition and metabolic parameters over
time, between men and women, the CLA and control groups.
Where there were significant effects attributed to gender differ-
ences, we subsequently adjusted for body composition. All
results are presented as means and standard deviations, and
a , 0·05 was considered to be statistically significant.
Results
Subject characteristics
Subjects were non-obese, regularly exercising men and women,
withmean ages of 32 (SD 7) years. ThemeanBMI andVO2max for
men and women were 22·5 (SD 2·5) and 24·2 (SD 2·1) kg/m2, and
41·2 (SD 6·0) and 50·8 (SD 7·5) ml/kg per min, respectively. Sub-
ject characteristics are presented in Table 1. Groups were well
matched for age, mass and anthropometrical characteristics.
However, there was a significant difference in dietary restraint
between the males in the control and CLA groups. When
included as a covariate in the analysis, dietary constraint did
not alter any of the subsequent relationships.
Compliance and tolerance
Sixty-two of the sixty-four subjects completed the trial. Two
subjects withdrew from the trial, one due to personal reasons
and the other due to medical reasons. The pill compliance was
above 90% in both groups (93·9 (SD 6·5) v. 95·2 (SD 6·0) %,
for CLA and control groups, respectively). No subjects were
excluded on the basis of non-compliance and co-varying for
compliance in the statistical analysis did not alter any of the
relationships.
The capsules were well-tolerated, with only a few subjects
reporting sporadic adverse events. The adverse events reported
in the CLA and control groups were headaches (6% v. 16%),
bloating (29% v. 23%), diarrhoea (48% v. 35%), flatulence
(16% v. 0%), skin irritation (13% v. 19%), and flu or cold
(32% v. 42%), respectively. However, the occurrence of
adverse events did not differ significantly between the groups.
Body composition
Body composition changes over the 12-week period are also
presented in Table 1. CLA supplementation was not associated
with any statistically significant changes in body mass or body
composition in men or women. There were also no significant
changes in regional body fat distribution in either group
(Table 2), measured using either anthropometry (waist and
hip circumferences) or CT.
Glucose tolerance and insulin sensitivity
The results of the OGTT are presented in Tables 3–5.
Plasma glucose concentrations were not different in response
to an oral glucose load in either of the groups and in men
Table 1. Body composition changes prior to (pre) and following (post) 12 weeks of conjugated linoleic
acid (CLA) administration*
(Mean values and standard deviations)
CLA Control
Pre Post Pre Post
Mean SD Mean SD Mean SD Mean SD
Men
Mass (kg) 79·6 7·8 80·2 7·8 77·9 8·2 78·0 7·4
S skinfolds (mm) 75·2 24·3 76·5 24·8 83·7 30·8 83·3 28·0
% Fat (DEXA) 18·2 5·4 18·6 5·7 18·3 9·3 18·8 8·2
Fat-free (DEXA) (kg) 62·0 5·5 62·2 5·8 60·2 4·7 60·1 4·6
Women
Mass (kg) 60·0 11·4 61·4 9·2 62·4 6·3 62·3 7·1
S skinfolds (mm) 107·0 21·3 96·9 21·2 117·9 25·0 113·8 25·7
% Fat (DEXA) 29·2 6·7 28·2 6·4 32·4 6·1 32·2 6·1
Fat-free (DEXA) (kg) 41·9 4·8 41·7 5·2 40·7 3·5 40·2 3·7
DEXA, dual-energy X-ray absorptiometry.
* For details of procedures, see Methods section.
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and women following the 12-week intervention period.
Although plasma glucose concentrations were not different
between groups, mean plasma insulin concentrations (at 0,
30, 120min) were statistically lower in women taking
CLA following the 12-week intervention period, compared
to the control group of women (P¼0·04, gender £
time £ treatment interaction; mean values presented in
Fig. 1). A significant association was found between
the change in mean plasma insulin concentrations over the
12-week intervention, and the change in body fat (r 0·36,
P¼0·032). Similarly, mean serum NEFA concentrations
were significantly attenuated in response to an oral glucose
load after 12 weeks of supplementation in the CLA group
compared to the control group (P¼0·001, time £ treatment
interaction).
Insulin sensitivity, as measured by the increment in
glucose concentrations (0–30min) v. the increment in insulin
concentrations, and by the QUICKI model (Matsuda &
DeFronzo, 1999; Perseghin et al. 2001), insulin resistance
measured using the HOMA model (Matthews et al. 1985),
and the fasting glucose/insulin ratio, were not significantly
different between treatment or control groups, in men or
women (Table 6).
Blood lipid profiles
Blood lipid profiles are presented in Table 7. Significant
decreases were found in serum total cholesterol and LDL con-
centrations in both groups and decreases in HDL-cholesterol
concentrations in women only, over the 12-week intervention
(P¼0·001, P¼0·017 and P¼0·02, respectively). However,
after covarying for body composition, these differences were
no longer significant, nor were there significant changes in
serum triacylglycerol concentrations in response to CLA
supplementation.
Table 2. Regional body composition prior to (pre) and following (post) 12 weeks of conjugated linoleic acid (CLA) administration*
(Mean values and standard deviations)
CLA Control
Pre Post Pre Post
Mean SD Mean SD Mean SD Mean SD
Men
Waist (cm) 87·9 8·4 88·7 6·8 89·1 5·1 88·9 4·9
Waist/hip ratio 0·94 0·07 0·94 0·05 0·92 0·07 0·95 0·06
Visceral AT area (cm2) 6081 3242 6292 3029 5163 2584 5406 2517
Subcutaneous AT area (cm2) 12 353 6459 12 692 7201 13 572 7515 14 117 7393
Women
Waist (cm) 75·0 4·9 73·2 6·4 77·0 6·1 76·4 5·1
Waist/hip ratio 0·84 0·08 0·81 0·03 0·83 0·07 0·82 0·03
Visceral AT area (cm2) 3609 1530 3621 1534 4247 1754 4407 1900
Subcutaneous AT area (cm2) 15 075 5127 14 445 4866 20 182 7341 20 214 7681
AT, adipose tissue.
* For details of procedures, see Methods section.
Table 3. Changes in plasma glucose concentrations (mmol/l) in response to an oral glucose load, prior to (Pre)
and following (post) the 12-week conjugated linoleic acid (CLA) intervention period*
(Mean values and standard deviations)
0 30 min 60 min 90 min 120 min
Mean SD Mean SD Mean SD Mean SD Mean SD
CLA
Men
Pre 4·98 0·38 7·84 1·92 7·12 2·39 5·44 1·31 4·90 2·44
Post† 4·29 0·36 7·40 1·10 6·23 2·29 5·30 1·83 3·95 1·13
Women
Pre 4·77 0·38 6·72 0·99 5·73 1·53 5·22 1·21 4·73 1·05
Post† 3·97 0·49 5·38 1·08 4·51 1·62 3·73 0·74 3·32 0·70
Control
Men
Pre 4·96 0·34 7·22 1·13 6·42 1·65 4·99 1·21 4·20 1·16
Post† 4·33 0·38 6·57 0·91 5·41 1·02 4·53 0·86 3·61 0·80
Women
Pre 4·79 0·42 7·07 1·37 6·48 1·84 5·80 1·65 5·00 1·27
Post† 4·11 0·28 6·38 1·22 5·45 1·80 4·59 1·25 3·98 1·28
* For details of procedures, see Methods section.
†P,0·05, plasma glucose concentrations were lower in both groups following the 12-week intervention.
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RMR, substrate utilisation at rest and during sub-maximal
exercise
Resting RER and RMR, expressed in absolute (MJ/d) or rela-
tive (kJ/kg fat-free mass (FFM) per d) terms, did not change in
response to CLA treatment over 12 weeks, in either men or
women. However, absolute RMR decreased with weight loss
in both groups, and RER increased significantly from pre- to
post-testing (P,0·001). There were also no significant differ-
ences in response to the CLA treatment over 12 weeks in sub-
strate utilisation during sub-maximal exercise at 25% and
50% of VO2max (Table 8).
Ratings of hunger, fullness, prospective consumption
and satisfaction
CLA supplementation did not alter fasting measures of
appetite at any stage during the trial in either men or
women (data not shown). There were also no differences
in perception of hunger, fullness, prospective consumption
and satiety following the standardised breakfast. This was
true, irrespective of whether the data were expressed as
area under the curve, means or by comparing each time-
point. Mean values for satiety, in response to the standar-
dised breakfast, over the 12-week intervention period are
presented in Fig. 2.
Dietary intake and training
There were no systematic or statistically significant changes in
nutrient or energy intake (data not shown), or in training fre-
quency reported at the beginning, mid-way or at the end of the
trial. In women, physical activity, measured as MET-h/week,
was 13·1 (SD 8·3) and 11·2 (SD 6·9) h at baseline and 13·0
(SD 8·3) and 9·4 (SD 7) h at 12 weeks in the CLA and control
groups, respectively. In men, physical activity was 11·8
(SD 5·8) and 14·8 (SD 12·5) h at baseline and 14·7 (SD 5·9)
and 10·8 (SD 5·9) h at 12 weeks in the CLA and control
groups, respectively.
Discussion
The main finding of the present study was that mixed isomer
CLA administration (c9t11 isomer (29·7%) and c10t12 isomer
(30·9%), 3·9 g/d for 12 weeks) significantly reduced plasma
insulin concentrations in response to an oral glucose chal-
lenge, in non-obese regularly exercising women. Furthermore,
NEFA concentrations were significantly attenuated in
response to oral glucose, in both men and women in the
CLA group. The changes in plasma insulin concentrations
with CLA supplementation may be attributable, in part, to
changes in body composition, as those individuals who lost
the greatest amount of body fat also had an associated
Table 4. Changes in plasma insulin concentration (mU/ml) in response to an oral glucose load, prior to (pre) and following (post)
the 12-week conjugated linoleic acid (CLA) intervention period*
(Mean values and standard deviations)
CLA Control
0 30 min 120 min 0 min 30 min 120 min
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Men
Pre 5·5 2·1 45·1 19·2 18·7 16·2 4·9 3·1 37·6 24·3 21·2 20·0
Post 6·4 3·4 53·8 25·1 22·3 20·5 5·9 3·4 49·6 23·1 19·0 18·1
Women
Pre 3·6 2·9 42·4 13·7 27·0 19·1 4·9 2·7 38·6 16·5 27·7 17·2
Post† 4·1 2·6 38·7 19·9 18·5 9·1 5·8 2·3 45·4 16·3 26·7 15·1
* For details of procedures, see Methods section.
†P¼0·05, group £ trial £ time interaction.
Table 5. Changes in serum NEFA concentration (mmol/l) in response to an oral glucose load, prior to (pre) and following (post) the
12-week conjugated linoleic acid (CLA) intervention period*
(Mean values and standard deviations)
CLA Control
0 60 min 120 min 0 min 60 min 120 min
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Men
Pre 0·47 0·19 0·12 0·06 0·06 0·02 0·35 0·19 0·11 0·07 0·07 0·05
Post 0·33 0·17 0·07 0·04 0·09 0·16 0·31 0·16 0·07 0·04 0·08 0·11
Women
Pre 0·49 0·35 0·07 0·06 0·04 0·03 0·43 0·23 0·08 0·07 0·05 0·03
Post† 0·32 0·20 0·04 0·03 0·05 0·06 0·45 0·23 0·07 0·04 0·03 0·05
* For details of procedures, see Methods section.
†P,0·01, group £ trial £ time interaction.
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decrease in mean plasma insulin concentrations (r 0·38, CLA
group).
To our knowledge, this is the first controlled, clinical trial
that has demonstrated this effect in normal-weight persons
who are regularly exercising. Recently, a study undertaken
in young, sedentary individuals found that 8 weeks of sup-
plementation with a mixed isomer CLA, similar in content
and dose to the present study, resulted in a significant decrease
in mean fasting insulin concentrations, as well as an improved
insulin sensitivity index in six of the ten subjects undergoing
supplementation. This occurred despite no significant changes
in body composition (Eyjolfson et al. 2004).
The results of Eyjolfson et al. (2004) are in contrast to
previous studies in normoglycaemic individuals, in which
CLA administration was associated with increased plasma
insulin concentrations, suggesting decreased insulin sensi-
tivity (Medina et al. 2000), and in Type 2 diabetics, in
whom fasting glucose increased and insulin sensitivity
decreased with CLA supplementation (Moloney et al.
2004). The apparent adverse effect of CLA supplementation
on insulin resistance originally appeared to be isomer-
specific. For example, in recent studies of abdominally
obese men, treatment with dietary t10c12 isomer-enriched
CLA (3·4 g/d for 12 weeks) resulted in significantly
increased insulin resistance and blood glucose levels, com-
pared to the mixed isomer or placebo controls (Risérus
et al. 2001). More recently, however, this same group of
researchers studied twenty-five abdominally obese men, sup-
plemented for 12 weeks with c9,t11-enriched CLA (83%;
Risérus et al. 2004a). In their study, insulin sensitivity, as
measured by the euglycaemic clamp technique, was reduced
by 15% in the CLA group, compared to the control group.
This is the first such study showing adverse effects of the
c9t11 isomer-enriched CLA on insulin sensitivity in man,
and thus, the isomer-specific effects are not consistent.
The findings of reduced plasma insulin and serum NEFA
concentrations in response to the same level of glycaemia in
the present study may suggest improved insulin sensitivity
with CLA supplementation in the already insulin-sensitive
women. Differences between the work of Risérus et al.
(2001, 2004a,b) and the present study, as well as that of Eyolf-
son et al. (2004) may be due, in part, to the fact that subjects
were young adults, and not overweight. Furthermore, in both
of these studies, subjects were ingesting a similar amount of
mixed-isomer CLA. However, further human studies are rec-
ommended, in order to determine the specific mechanisms
underlying these effects, in particular, the isomer-specific
nature of the adaptations, and any potential adverse effects
and dose–response relationships in obese or insulin-resistant
individuals.
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Fig. 1. Mean plasma insulin concentrations in women prior to (pre) and follow-
ing (post) a 12-week intervention of conjugated linoleic acid (CLA). For details
of procedures, see Methods section. Values are means with their standard
deviations depicted by vertical bars. *P¼0·05 for group £ trial interaction.
Table 6. Measures of insulin sensitivity and insulin resistance prior to (pre) and following (post) the 12-week conjugated
linoleic acid (CLA) intervention period*
(Mean values and standard deviations)
CLA Control
Pre Post Pre Post
Measures† Mean SD Mean SD Mean SD Mean SD
Men
30 min insulin/glucose increment 14·2 6·9 14·7 6·2 14·4 17·5 25·2 14·8
HOMA-R 1·21 0·44 1·22 0·62 1·08 0·68 1·15 0·67
Fasting insulin/glucose 1·07 0·51 0·96 0·75 1·43 1·07 1·79 3·16
QUICKI (Gb, Ib) 0·38 0·03 0·39 0·04 0·39 0·04 0·42 0·12
QUICKI (Gb, Ib, NEFAb) 0·45 0·07 0·49 0·07 0·51 0·12 0·54 0·18
Women
30 min insulin/glucose increment 19·1 43·8 25·1 22·1 16·5 11·3 23·1 17·1
HOMA-R 0·77 0·62 0·72 0·47 1·04 0·58 1·07 0·44
Fasting insulin/glucose 3·46 5·7 2·31 3·8 1·37 0·94 0·96 0·80
QUICKI (Gb, Ib) 0·44 0·11 0·44 0·10 0·40 0·04 0·39 0·04
QUICKI (Gb, Ib, NEFAb) 0·51 0·11 0·58 0·18 0·48 0·09 0·47 0·09
* For details of procedures, see Methods section.
† For details of measures, see Methods section.
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In the present study, reduced plasma insulin concentrations
at the same level of glycaemia in the CLA women were not
reflected in the indexed measures of insulin resistance
(HOMA) or insulin sensitivity (QUICKI), although there
was a trend towards improved insulin sensitivity (P,0·08).
This is likely due to the fact that these indices have been
developed, in part, to establish a more easily administered
reference for insulin. In the current study sample, subjects
were generally insulin-sensitive, and found to be at the
higher range of values previously reported for non-diabetic,
control populations for QUICKI, and at the very low range
of values for HOMA-IR (Phillips et al. 1994; Perseghin et al.
2001). Therefore, these indices may not be as sensitive to
change in the extreme ranges, and in non-diabetic, non-
obese, fit individuals.
Body composition
In the present study we failed to find an association between
CLA administration and changes in body composition. In
human studies, the effects of CLA supplementation on
body composition have been inconsistent. For example, in
a small, placebo-controlled study of healthy, non-obese
women, 3·9 g/d mixed isomer CLA, containing smaller
quantities of the c9t11 and t10c12 isomers, over 64 d, had
no effect on body fat content (Zambell et al. 2000). Conver-
sely, in studies of overweight men and women (Blankson
et al. 2000) and abdominally obese men (Risérus et al.
2001), CLA supplementation over several weeks (amounts
ranged from 3·4 to 6·8 g/d mixed isomer composition
(.36% t10c12 and c9t11 isomers) for 12 weeks, or 4·2 g/
d for 4 weeks) resulted in significant body fat losses. In
another recent study, as little as 1·8 g CLA/d resulted in a
significant reduction in body fat percentage in healthy,
non-overweight men and women, who exercised for
90min, three times weekly (Thom et al. 2001). Differences
between studies may be linked, in part, to the composition
of the placebo control capsules, or the isomeric mix of
the CLA supplement.
As training and dietary intake did not change in the present
study, it is unlikely that these factors played a confounding
role for effects of CLA on body composition.
Table 7. Serum lipid profiles prior to (pre) and following (post) the 12-week conjugated linoleic acid
(CLA) intervention period*
(Mean values and standard deviations)
CLA Control
Pre Post Pre Post
Mean SD Mean SD Mean SD Mean SD
Men
TC (mmol/l)† 4·3 1·3 4·1 1·0 4·7 1·3 4·4 0·8
LDL-C (mmol/l)‡ 2·2 1·0 2·0 0·7 2·7 1·2 2·4 0·8
HDL-C (mmol/l)§ 1·3 0·5 1·3 0·4 1·3 0·3 1·4 0·3
TG (mmol/l)k 1·92 1·42 1·96 0·89 1·38 0·77 1·28 0·51
Women
TC (mmol/l)† 4·9 1·2 4·4 0·9 4·7 1·1 4·1 0·8
LDL-C (mmol/l)‡ 2·6 1·1 2·4 0·8 2·4 0·8 2·2 0·8
HDL-C (mmol/l)§ 1·7 0·4 1·5 0·4 1·6 0·3 1·4 0·3
TG (mmol/l)k 1·16 0·42 1·14 0·40 1·40 0·55 1·14 0·35
HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; TC, total cholesterol; TG, triacylglycerol.
* For details of procedures, see Methods section.
Changes pre–post in both groups: †P¼0·001, ‡P¼0·017; §P¼0·02.
kP¼0·03, time £ treatment interaction.
Table 8. RMR and RER at rest and during sub-maximal exercise at 25 % and 50 % of VO2max, prior to (pre) and
following (post) the 12-week conjugated linoleic acid (CLA) intervention period*
(Mean values and standard deviations)
CLA Control
Pre Post Pre Post
Mean SD Mean SD Mean SD Mean SD
RMR (MJ/d)† 6·5 1·0 6·3 1·1 6·8 1·1 6·4 1·1
Resting RER (VCO2/VO2)† 0·76 0·04 0·86 0·07 0·77 0·06 0·88 0·08
RER at 25 % PPO (VCO2/VO2) 0·85 0·03 0·88 0·04 0·87 0·03 0·87 0·04
RER at 50 % PPO (VCO2/VO2) 0·90 0·04 0·92 0·03 0·91 0·03 0·92 0·03
PPO, peak sustained power output.
* For details of procedures, see Methods section.
† Changes pre–post in both groups, no group or interaction effects (P,0·001).
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Regional adipose tissue distribution
Unlike previous studies in abdominally obese individuals sup-
plemented with CLA (Risérus et al. 2001), we were unable to
detect differences in regional adipose tissue distribution, visc-
eral or subcutaneous adipose tissue area, using anthropometri-
cal measures and CT scans, which may not be sensitive
enough to detect small changes in body fat distribution
expected in non-obese, physically fit individuals.
Plasma lipoprotein levels
In the present study, we found a reduction in serum HDL-
cholesterol and total cholesterol concentrations, in both
groups of women, however there was no treatment effect of
CLA. This is in agreement with other human trials, in which
CLA supplementation (at similar concentrations for reason-
ably similar time periods) did not significantly alter plasma
lipoprotein or serum triacylglycerol concentrations in
normal-weight and overweight individuals (Benito et al.
2000; Risérus et al. 2001). More recently, Noone et al.
(2002) demonstrated that supplementation with a 50:50
blend of c9t11:t10c12 isomers of CLA for 8 weeks signifi-
cantly reduced fasting triacylglycerol concentrations, whereas
supplementation with an 80:20 blend of c9t11:t10c12 isomers
of CLA reduced VLDL-cholesterol concentrations in fifty-one
normolipidaemic subjects, without altering LDL-cholesterol or
HDL-cholesterol concentrations.
The decrease in total cholesterol and HDL-cholesterol
seen in both groups of women over the 12-week interven-
tion period may be a consequence of increased awareness
and self-monitoring of dietary intake, or the unlikely result
of subtle changes in dietary fatty acid intake, and/or
training. However, these changes are usually described
in persons who have undergone weight loss (Sartorio
et al. 2001).
The effects of dietary CLA supplementation (in the range of
0·1% of dietary energy) on lipoprotein metabolism are, thus
far, inconsistent. The conflicting results regarding CLA sup-
plementation and lipoprotein metabolism may be due to gen-
etic susceptibility, differences in dose-response, isomer
content and the levels of intake of dietary fat, and specific
fatty acids. In addition, the placebo control used in trials
varies greatly, including olive oil, linoleic acid, safflower
oil, soya oil and sunflower oil. This may explain, in part,
the lack of consistent results of CLA supplementation on
plasma lipid profiles.
Appetite and measures of satiety
In the present study, CLA supplementation did not alter
short-term appetite, measured using a VAS, nor hunger, sati-
ety, fullness and desire to eat, preceding and for 3 h following
a standardised breakfast. The present results are in agreement
with a study by Medina et al. (2000), in a small sample of
normal-weight women, in which appetite was measured over
a 9-week period of CLA supplementation. Medina et al.
(2000) postulated that this method may not be sufficiently sen-
sitive to identify subtle changes in appetite.
In contrast, in a recent study by Kamphuis et al. (2003b),
they observed increases in ratings of fullness and satiety and
decreased ratings of hunger, in response to a standardised
meal, in fifty-four overweight subjects over 13 weeks of sup-
plementation at dosages of either 1·8 or 3·6 g CLA/d. How-
ever, prior to CLA supplementation, subjects had followed a
very low-energy diet (2·1MJ/d) for 3 weeks.
Differences between these studies may be a result of differ-
ences in energy or macronutrient composition of the standar-
dised breakfast, or a consequence of protocol variations. For
example, in the study by Kamphuis et al. (2003b), CLA sup-
plementation was preceded by a short-term period of dieting,
and consisted of a single pre-breakfast measure. In the present
study, repeated VAS tests were conducted, before a standar-
dised breakfast and in the 2 h period following the breakfast.
It is also possible that hunger and satiety ratings should
have been monitored for a longer period of time (.4·5 h),
as the VAS technique is shown to be more valid and correlates
best to subsequent energy intake if measured over 4 h follow-
ing the standardised meal (Flint et al. 2000).
Resting energy expenditure and substrate oxidation at rest
and during exercise
Finally, in the present study, we found no differences between
treatment groups in changes in resting energy expenditure, or
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Fig. 2. Mean satiety scores for women (a) and men (b) for the conjugated linoleic acid (CLA, A) and control groups (†, B). For details of procedures, see
Methods section. Values are means with their standard deviations depicted by vertical bars. There were no effects of CLA on satiety, however, in the men, the
control group had a higher overall satiety level (gender £ group interaction, P¼0·02).
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in substrate oxidation at rest associated with weight loss, nor
during exercise. The present results are in agreement with
the study by Zambell et al. (2000), in which no changes
were found in resting energy expenditure, RER or fat oxi-
dation at rest. In contrast, increased resting energy expenditure
was demonstrated in overweight individuals who were sup-
plemented with CLA after having lost weight, using very
low-energy diets (Kamphuis et al. 2003a). In the present
study, however, the increase in resting energy expenditure in
the CLA group was not significant after adjusting for lean
body mass.
Conclusion
The findings of the present study suggest that CLA (3·9 g/d,
12 weeks) supplementation resulted in significant and
favourable changes in plasma insulin and NEFA concen-
trations in response to an oral glucose load, suggesting
improved insulin sensitivity. However, these changes were
demonstrated in persons who were not overweight, and
were found specifically in regularly exercising women.
More studies are needed to further understand the mechan-
isms underlying these changes, and the possible modulating
role of gender, fitness and body fat levels on the physiologi-
cal response to CLA supplementation.
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